- Home
- XAIR vs PYPD Comparison
XAIR vs PYPD Comparison
Compare XAIR & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XAIR
- PYPD
- Stock Information
- Founded
- XAIR 2011
- PYPD 2008
- Country
- XAIR United States
- PYPD Israel
- Employees
- XAIR N/A
- PYPD N/A
- Industry
- XAIR Medical/Dental Instruments
- PYPD Medical/Dental Instruments
- Sector
- XAIR Health Care
- PYPD Health Care
- Exchange
- XAIR Nasdaq
- PYPD Nasdaq
- Market Cap
- XAIR 27.7M
- PYPD 30.1M
- IPO Year
- XAIR N/A
- PYPD 2020
- Fundamental
- Price
- XAIR $0.35
- PYPD $2.99
- Analyst Decision
- XAIR Strong Buy
- PYPD Strong Buy
- Analyst Count
- XAIR 4
- PYPD 2
- Target Price
- XAIR $3.67
- PYPD $10.50
- AVG Volume (30 Days)
- XAIR 1.4M
- PYPD 19.7K
- Earning Date
- XAIR 02-10-2025
- PYPD 02-12-2025
- Dividend Yield
- XAIR N/A
- PYPD N/A
- EPS Growth
- XAIR N/A
- PYPD N/A
- EPS
- XAIR N/A
- PYPD N/A
- Revenue
- XAIR $3,023,000.00
- PYPD N/A
- Revenue This Year
- XAIR $244.61
- PYPD N/A
- Revenue Next Year
- XAIR $258.76
- PYPD N/A
- P/E Ratio
- XAIR N/A
- PYPD N/A
- Revenue Growth
- XAIR 338.75
- PYPD N/A
- 52 Week Low
- XAIR $0.30
- PYPD $2.37
- 52 Week High
- XAIR $2.11
- PYPD $6.58
- Technical
- Relative Strength Index (RSI)
- XAIR 41.74
- PYPD 49.42
- Support Level
- XAIR $0.34
- PYPD $2.89
- Resistance Level
- XAIR $0.40
- PYPD $3.27
- Average True Range (ATR)
- XAIR 0.05
- PYPD 0.28
- MACD
- XAIR -0.00
- PYPD 0.00
- Stochastic Oscillator
- XAIR 10.21
- PYPD 45.89
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.